President Trump Signs Executive Order to Expedite Review of Psychedelics for Medical Use

President Donald Trump signed an executive order aimed at accelerating the review process for psychedelic drugs, including ibogaine, for use in treating serious mental illnesses. The order seeks to ease federal restrictions and encourage research into these substances, aligning with the administration's policy to fast-track innovative research and appropriate drug approvals to address the mental health crisis.